Clinical Trial Update: IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of bendamustine, rituximab, and pixantrone in relapsed/refractory B-cell non-Hodgkin's lymphoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Pixantrone (pixantrone)
• Rituximab (rituximab)

Snippet

Sponsor: Anne Beaven, MD | Conditions: Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2019-06-14